Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant therapy after tumor resection for non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation identified by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
Brought EGFR-targeted treatment to the postoperative setting for patients with specified mutations.
What research teams should watch
Use surgical tissue for timely testing and coordinate the postoperative adjuvant treatment sequence.
PRIMARY RECORDS